Anti-PD-1 monotherapy versus anti-PD1 plus anti-CTLA4 in advanced melanoma: how do we decide?

Melanoma Manag. 2017 Sep;4(3):151-155. doi: 10.2217/mmt-2017-0016. Epub 2017 Aug 2.

Authors

Lewis Au¹, Aine O'Reilly¹, James Larkin¹

Affiliation

¹ The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.

No abstract available

Keywords: anti-CTLA4; anti-PD-1; combination therapy; immunotherapy; metastatic melanoma.

Publication types

Editorial